このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

vTv Therapeutics マネジメント

マネジメント基準チェック /24

vTv Therapeutics'の CEO はPaul Sekhriで、 Aug2022年に任命され、の在任期間は 1.83年です。の年間総報酬は$ 650.91Kで、 73.7%給与と26.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.6%を直接所有しており、その価値は€ 355.38K 。経営陣と取締役会の平均在任期間はそれぞれ1.5年と0.3年です。

主要情報

Paul Sekhri

最高経営責任者

US$650.9k

報酬総額

CEO給与比率	73.7%
CEO在任期間	1.9yrs
CEOの所有権	0.6%
経営陣の平均在職期間	1.6yrs
取締役会の平均在任期間	less than a year

経営陣の近況

Recent updates

CEO報酬分析

vTv Therapeutics の収益と比較して、Paul Sekhri の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$651k	US$480k	-US$20m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	US$2m	US$200k	-US$19m

報酬と市場: Paulの総報酬 ($USD 650.91K ) は、 German市場 ($USD 512.00K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Paulの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Paul Sekhri (66 yo)

1.9yrs

在職期間

US$650,913

報酬

Mr. Paul J. Sekhri, M.Sc. is Director at AdhereTech Inc. since February 7, 2024. He serves as Chief Executive Officer, President & Director of vTv Therapeutics Inc. since august 01, 2022 and also serves as...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Paul Sekhri	CEO, President & Chairman of the Board	1.9yrs	US$650.91k	0.60% $ 306.4k
Steven Tuch	Executive VP & CFO	1.6yrs	US$465.25k	0.21% $ 108.6k
Carmen Valcarce	Chief Scientific Officer & Executive VP	no data	データなし	データなし
Elizabeth Keiley	Executive VP & General Counsel	1.4yrs	データなし	データなし
Richard Nelson	Executive VP of Corporate Development & Director	1.9yrs	US$547.40k	0.45% $ 226.9k
Thomas Strack	Chief Medical Officer	less than a year	データなし	データなし

1.6yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: 5VT0の経営陣は経験豊富とはみなされません ( 1.5年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Paul Sekhri	CEO, President & Chairman of the Board	1.9yrs	US$650.91k	0.60% $ 306.4k
Richard Nelson	Executive VP of Corporate Development & Director	3.7yrs	US$547.40k	0.45% $ 226.9k
Daniel Spiegelman	Director	less than a year	データなし	データなし
Srinivas Akkaraju	Independent Director	less than a year	データなし	データなし
Anne Phillips	Independent Director	less than a year	データなし	データなし
Raymond Cheong	Lead Independent Director	less than a year	データなし	データなし
Fahed Al-Marzooqi	Independent Director	2yrs	US$87.63k	0.026% $ 13.0k

0.4yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: 5VT0の取締役会は経験豊富ではない ( 0.3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

vTv Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

High number of new and inexperienced directors

vTv Therapeutics Inc., Annual General Meeting, Jun 11, 2024

vTv Therapeutics Inc. Announces Board Changes

Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors

Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer

vTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel

Recent updates

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

High number of new and inexperienced directors

vTv Therapeutics Inc., Annual General Meeting, Jun 11, 2024

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million.

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million.

vTv Therapeutics Inc. Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics Inc. Announces Board Changes

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4.923802 million.

Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors

vTv Therapeutics Receives Non-Compliance Notice From Nasdaq

Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer

New major risk - Share price stability

New major risk - Negative shareholders equity

First half 2023 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1H 2022)

Nasdaq Approves vTv Therapeutics' Request to Extend the Period to Regain Compliance with the Minimum Bid Requirement Until December 18, 2023

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.10 loss in 1Q 2022)

vTv Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.26 loss per share (vs US$0.21 loss in FY 2021)

vTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel

vTv Therapeutics Receives a Letter from NASDAQ Regarding Minimum Bid Price

vTv Therapeutics Inc. Appoints Steven Tuch as Chief Financial Officer

Third quarter 2022 earnings released: US$0.053 loss per share (vs US$0.018 loss in 3Q 2021)

High number of new directors

Third quarter 2022 earnings released: US$0.053 loss per share (vs US$0.018 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.01 loss in 2Q 2021)

vTv Therapeutics Inc. Appoints Jonathan Isaacsohn as Member and Chair of the Board

High number of new directors

vTv Therapeutics Inc. Announces CEO Changes

Jon Isaacsohn to Join the vTv Therapeutics Inc. Board of Directors

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

vTv Therapeutics Inc. announced that it expects to receive $24.999762 million in funding from G42 Investments Ai Holding Rsc Ltd

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.075 loss in 1Q 2021)

vTv Therapeutics Inc., Annual General Meeting, Jun 01, 2022

Robin E. Abrams Resigns as Executive Chairperson of the Board of Directors of vTv Therapeutics Inc

vTv Therapeutics Inc. Announces Not to Stand for Re-Election of Noel Spiegel as Director and Chair of the Audit Committee of the Board

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020)

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Inc. Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

vTv Therapeutics Inc.(NasdaqCM:VTVT) dropped from Russell 3000E Index

First quarter 2021 earnings released: US$0.075 loss per share (vs US$0.11 loss in 1Q 2020)

vTv Therapeutics Inc. Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

Director recently bought €142k worth of stock

Full year 2020 earnings released: US$0.18 loss per share (vs US$0.59 loss in FY 2019)

Revenue beats expectations

vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes

vTv Therapeutics Inc. Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Announces Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

New 90-day high: €1.83

vTv Therapeutics Inc. Appoints Rich Nelson as A Member of the Board

Revenue in line with expectations

vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study

Edward P. Taibi Resigns from the Board of Directors of vTv Therapeutics, Inc

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24